Speech and Voice Disorders in Parkinson's Disease

Parkinson's Disease: Non-Motor and Non-Dopaminergic Features

Volumn , Issue , 2011, Pages 346-360

  Ramig, Lorraine ^a,b,c   Fox, Cynthia ^a,b   Sapir, Shimon ^d  

^a UNIVERSITY OF COLORADO   (United States)

^b University of Arizona   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d UNIVERSITY OF HAIFA   (Israel)

Author keywords

LSVT; Parkinson's disease; Speech; Voice

Indexed keywords

EID: 84862698117     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444397970.ch31     Document Type: Chapter

References (203)

1. Ho A, Iansek R, Marigliani C, et al. Speech impairment in a large sample of people with Parkinson's disease. Behav Neurol 1998;11:131-7.
2. Aronson AE. Clinical Voice Disorders. New York: Thieme-Stratton, 1990.
3. Logemann J, Fisher H, Boshes B, Blonsky E. Frequency and concurrence of vocal tract dysfunctions in the speech of a large sample of Parkinson patients. Speech Hear Disord 1978;43:47-57.
4. Stewart C, Winfield L, Hunt A, et al. Speech dysfunction in early Parkinson's disease. Moo Disord 1995;10:562-5.
5. Sapir S, Pawlas AA, Ramig LO, et al. Voice and speech abnormalities in Parkinson disease: relation to severity of motor impairment, duration of disease, medication, depres-sion, gender, and age.] Med Speech Lang Pathol 2001;9:213-26.
6. Sapir S, Spielman J, Ramig L, et al. Effects of intensive voice treatment (LSVT) on vowel articulation in dysarthric indi-viduals with idiopathic Parkinson disease: acoustic and per-ceptual findings. Speech Lang Hear Res 2007;50:899-912.
7. Dowding CH, Shenton CL, Salek SS. A review of the health-related quality of life and economic impact of Parkinson's disease. Drugs Aging 2006;23:693-721.
8. Findley LJ. The economic impact of Parkinson's disease. Parkinsonism Relat Disord 2007;13(Suppl): S8-12.
9. Miller N, Noble E, Jones D, Burn D. Hard to swallow: dys-phagia in Parkinson's disease. Age Ageing 2006;35:614-8.
10. Miller N, Noble E, Jones D, Burn D. Life with communication changes in Parkinson's disease. Age Ageing 2006;35:235-9.
11. Miller N, Allcock L, Jones D, et al. Prevalence and pattern of perceived intelligibility changes in Parkinson's disease. Neurol Neurosurg Psychiatry 2007;78:1188-90.
12. Pell MD, Cheang HS, Leonard CL. The impact of Parkinson's disease on vocal-prosodic communication from the perspective of listeners. Brain Lang 2006;97:123-34.
13. Pitcairn TK, Clemie S, Gray JM, Pentland B. Non-verbal cues in the self-presentation of parkinsonian patients. Br] Clin Psy-chol 1990;29:177-84.
14. Fox C, Ramig L. Vocal sound pressure level and self-perception of speech and voice in men and women with idiopathic Parkinson disease. Am J Speech Lang Pathol 1997;2:29-42.
15. Miller N, Noble E, Jones D, et al. How do I sound to me? Perceived changes in communication in Parkinson's disease. Clin Rehabil 2008;22:14-22.
16. Ramig L, Fox C, Sapir S. Speech treatment for Parkinson dis-ease. Expert Rev Neurother 2008;8:299-311.
17. Sapir S, Ramig L, Fox C. Voice, speech and swallowing disorders. In: Factor S, Weiner W, eds. Parkinson Disease: Diagnosis and Clinical Management. New York: Demos Medical Publishing, 2008: 77-97.
18. Sapir S, Ramig L, Fox C. The Lee Silverman Voice Treatment for voice, speech and other orofacial disorders in patients with Parkinson's disease. Fut Neurol 2006;1:563-70.
19. D'Amelio M, Ragonese P, Morgante L, et al. Long-term sur-vival of Parkinson's disease: a population-based study. J Neu-rol 2006;253:33-7.
20. Schenkman M, Zhu CW, Cutson TM, Whetten-Goldstein K. Longitudinal evaluation of economic and physical impact of Parkinson's disease. Parkinsonism Relat Disord 2001;2:41-50.
21. Wermuth L, Stenager EN, Stenager E, Boldsen J. Mortality in patients with Parkinson's disease. Acta Neurol Scand 1995;92:55-8.
22. Atarashi J, Uchida E. A clinical study of parkinsonism. Rec Adv Res Nerv Syst 1959;3:871-82.
23. Canter GJ. Speech characteristics of patients with Parkinson's disease: III. Articulation, diadochokinesis and overall speech adequacy. J Speech Hear Disord 1965;30:217-24.
24. Canter GJ. Speech characteristics of patients with Parkinson's disease: II. Physiological support for speech. J Speech Hear Dis-ord 1965;30:44-9.
25. Hartelius L, Svensson P. Speech and swallowing symptoms associated with Parkinson's disease and multiple sclerosis: a survey. Folia Phoniatr 1994;46:9-17.
26. Hoberman SG. Speech techniques in aphasia and parkinson-ism. J Mich State Med Soc 1958;57:1720-3.
27. Mutch R, Strucwick A, Roy S, et al. Parkinson's disease: dis-ability review and management. Br Med J 1986;293:675-7.
28. Oxtoby M. Parkinson's Disease Patients and Their Social Needs. London: Parkinson's Disease Society, 1982.
29. Scott S, Caird FI, Williams BO. Communication in Parkinson's Disease. Rockville, MD: Aspen, 1985.
30. Selby G. Parkinson's disease. In: Vinken PJ, Bruyn GW, eds. Handbook of Clinical Neurology. North-Holland: Amsterdam, 1968:173-211.
31. Streifler M, Hofman S. Disorders of verbal expression in parkinsonism. In: Hassler RG, Christ JF. eds. Advances in Neurology. New York: Raven Press, 1984:385-93.
32. Uziel A, Bohe M, Cadilhac J, et al. Les troubles de la voix et de la parole dans les syndromes parkinsoniens. Folia Phoniatr 1975;27:166-76.
33. Darley FL, Aronson AE, Brown JR Clusters of deviant speech dimensions in the dysarthrias. J Speech Hear Res 1969;12:462-9.
34. Darley FL, Aronson A, Brown J. Differential diagnostic pat-terns of dysarthria. J Speech Hear Res 1969;12:246-69.
35. Darley FL, Aronson AE, Brown JR. Motor Speech Disorders. Philadelphia: Saunders, 1975.
36. Logemann J, Boshes B, Fisher H. The steps in the degener-ation of speech and voice control in Parkinson's disease. In: Siegfried J, ed. Parkinson's Diseases: Rigidity, Akinesia, Behavior. Vienna: Hans Huber, 1973:101-12.
37. Ludlow CL, Bassich CJ. Relationships between perceptual ratings and acoustic measures of hypokinetic speech. In: McNeil MR, Rosenbek JC, Aronson AE, eds. The Dysarthrias:.
38. Skodda S, Visser W, Schlegel U. Vowel articulation in Parkinson's disease. J Voice 2010; Apr 30 [Epub ahead of print].
39. Moreau C, Ozsancak C, Blatt JL, et al. Oral festination in Parkinson's disease: biomechanical analysis and correlation with festination and freezing of gait. Mov Disord 2007;22:1503-1506.
40. Skodda S, Schlegel U. Speech rate and rhythm in Parkinson's disease. Mov Disord 2008;23:985-92.
41. Baumgartner CA, Sapir S, Ramig LO. Voice quality changes following phonatory-respiratory effort treatment (LSVT) versus respiratory effort treatment for individuals with Parkinson disease. J Voice 2001;15:105-14.
42. Sapir S, Ramig L, Hoyt P, et al. Speech loudness and quality 12 months after intensive voice treatment (LSVT) for Parkin-son's disease: a comparison with an alternative speech treat-ment. Folia Phoniatr 2002;54:296-303.
43. Ramig L. The role of phonation in speech intelligibility: a review and preliminary data from patients with Parkinson's disease. In: Kent RD, ed. Intelligibility in Speech Disorders: Theory, Measurement, and Management. Amsterdam: John Benjamin, 1992:119-56.
44. Sapir S, Ramig LO, Spielman JL, Fox C. Formant centraliza-tion ratio: a proposal for a new acoustic measure of dysarthric speech. J Speech Lang Hear Res 2010;53:114-25.
45. Fox C, Ramig L. Vocal sound pressure level and self-perception of speech and voice in men and women with idiopathic Parkinson disease. Am J Speech Lang Pathol 1997;6: 85-94.
46. King J, Ramig L, Lemke JH, Horii Y. Parkinson disease: lon-gitudinal changes in acoustic parameters of phonation. J Med Speech Lang Pathol 1994;2:29-42.
47. Winholtz W, Ramig L. The vocal demodulator for analysis of vocal tremor. J Speech Hear Res 1992;35:562-73.
48. Ramig L, Scherer R, Titze I, Ringel S. Acoustic characteristics of voice of patients with neurological disease: a preliminary report. Ann Otol Rhinol Laryngol 1988;97:164-72.
49. Smith M, Ramig LO, Dromey C, et al. Intensive voice treat-ment in Parkinson's disease: laryngostroboscopic findings. J Voice 1995;9:453-9.
50. Kleinow J, Smith A, Ramig, L. Speech stability in idiopathic Parkinson disease: effects of rate and loudness manipula-tions. J Speech Lang Hear Res 2001;44:1041-51.
51. Huber J, Stathopoulos E, Ramig L, Lancaster S. Respiratory function and variability in individuals with Parkinson dis-ease: pre and post Lee Silverman Voice Treatment (LSVT). J Med Speech Lang Pathol 2003;11:185-201.
52. Solomon NP, Hixon TJ. Speech breathing in Parkinson's dis-ease. J Speech Lang Hear Res 1993;36:294-310.
53. Baker K, Ramig LO, Luschei E, Smith M. Thyroarytenoid muscle activity associated with hypophonia in Parkinson dis-ease and aging. Neurology 1998;51(6): 1592-8.
54. Luschei ES, Ramig LO, Baker KL, et al. Discharge character-istics of laryngeal single motor units during phonation in young and older adults and in persons with Parkinson dis-ease. J Neurophys 1999;81:2131-9.
55. Caligiuri M. The influence of speaking rate on articula-tory hypokinesia in parkinsonian dysarthria. Brain Lang 1989;36:493-502.
56. Kempler D, Van Lancker D. Effect of speech task on intelligibility in dysarthria: a case study of Parkinson's disease. Brain Lang 2002;80:449-64.
57. Rosen KM, Kent RD, Duffy JR. Task-based profile of vocal intensity decline in Parkinson's disease. Folia Phoniatr 2005;57:28-37.
58. Ackermann H, Ziegler W. Articulatory deficits in parkinso-nian dysarthria: an acoustic analysis. J Neurol Neurosurg Psychiatry 1991;54:1093-8.
59. Zarzur AP, Duprat AC, Shinzato G, Eckley CA. Laryngeal electromyography in adults with Parkinson's disease and voice complaints. Laryngoscope 2007;117:831-4.
60. De Letter M, Santens P, De Bodt M, et al. The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson's disease. Clin Neurol Neurosurg 2007;109:495-500.
61. De Letter M, Santens P, Estercam I, et al. Levodopa-induced modifications of prosody and comprehensibility in advanced Parkinson's disease as perceived by professional listeners. Clin Linguist Phon 2007;21:783-91.
62. Ho AK, Bradshaw JL, Iansek FR. For better or worse: the effect of levodopa on speech in Parkinson's disease. Mov Dis-ord 2008;23:574-80.
63. Larson K, Ramig LO, Scherer RC. Acoustic and glottographic voice analysis during drug-related fluctuations in Parkin-son's disease. J Med Speech Lang Pathol 1994;2:211-26.
64. Goberman A. Correlation between acoustic speech character-istics and non-speech motor performance in Parkinson dis-ease. Med Sci Monit 2005;11:CR109-16.
65. Trail M, Fox C, Ramig LO, et al. Speech treatment for Parkinson's disease. NeuroRehabilitation 2005;20:205-21.
66. Goberman A, Coelho C, Robb M. Phonatory characteristics of parkinsonian speech before and after morning medication: the ON and OFF states. J Commun Disord 2002;35: 217-39.
67. Kompoliti K, Wang QE, Goetz CG, et al. Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. Neurology 2000;54:458-62.
68. Netsell R, Daniel B, Celesia GG. Acceleration and weakness in parkinsonian dysarthria. J Speech Hear Disord 1975;40: 170-8.
69. Fox C, Ramig L, Ciucci M, et al. The science and practice of LSVT/LOUD: neural plasticity-principled approach to treat-ing individuals with Parkinson disease and other neurological disorders. Semin Speech Lang 2006;27:283-99.
70. Forrest K, Weismer G, Turner GS. Kinematic, acoustic, and perceptual analyses of connected speech produced by Parkinsonian and normal geriatric adults. J Acoust Soc Am 1989;85:2608-22.
71. Ho AK, Iansek R, Bradshaw JL. Motor instability in parkin-sonian speech intensity. Neuropsychiatry Neuropsychol Behav Neurol 2001;14:109-16.
72. Liss JM, Spitzer SM, Caviness JN, Adler C. The effects of familiarization on intelligibility and lexical segmentation in hypokinetic and ataxic dysarthria. J Acoust Soc Am 2002;112:3022-30.
73. Dromey C, Ramig L. Intentional changes in sound pressure level and rate: Their impact on measures of respiration, phonation, and articulation. J Speech Lang Hear Res 1998;41:1003-18.
74. Goberman AM, Elmer LW. Acoustic analysis of clear versus conversational speech in individuals with Parkinson disease. J Commun Disord 2005;38:215-30.
75. Caligiuri M, Abbs JH. Response properties of the peri-oral reflex in Parkinson's disease. Exp Neurol 1987;98: 563-72.
76. Diamond SG, Schneider JS, Markham CH. Oral sensorimo-tor defects in people with Parkinson's disease. Adv Neurol 1987;45:335-8.
77. Schneider JS, Diamond SG, Markham CH. Deficits in orofa-cial sensorimotor function in Parkinson's disease. Ann Neurol 1986;19:275-82.
78. Schneider JS, Lidsky TI. Basal Ganglia and Behavior: Sensory Aspects of Motor Functioning. Toronto: Hans Huber, 1987.
79. Ho AK, Iansek R, Bradshaw JL. Regulations of parkinsonian speech volume: the effect of interlocuter distance. J Neurol Neurosurg Psychiatry 1999;67:199-202.
80. Ho AK, Bradshaw JL, Iansek T. Volume perception in parkin-sonian speech. Mov Disord 2000;15:1125-31.
81. Ho AK, Bradshaw JL, Iansek R, Alfredson R. Speech volume regulation in Parkinson's disease: effects of implicit cues and explicit instructions. Neuropsychologia 1999;37:1453-60.
82. Graber S, Hertrich I, Daum I, et al. Speech perception deficits in Parkinson's disease: Underestimation of time intervals compromises identification of durational phonetic contrasts. Brain Lang 2002;82:65-74.
83. Solomon NP, Robin DA, Lorell DM, et al. Tongue function testing in Parkinson's disease: indicators of fatigue. In: Till JA, Yorkston KM, Beukelman R, eds. Motor Speech Disorders: Advances in Assessment and Treatment. Baltimore, MD: Paul H. Brooks, 1994: 147-60.
84. Fox CM, Morrison CE, Ramig LO, Sapir S. Current perspec-tives on the Lee Silverman Voice Treatment (LSVT) for people with idiopathic Parkinson's disease. Am J Speech Lang Pathol 2002;11:111-23.
85. Demirci M, Grill S, McShane L, Hallett M. A mismatch between kinesthetic and visual perception in Parkinson's dis-ease. Ann Neurol 1997;41:781-8.
86. Jobst EE, Melnick ME, Byl NN, et al. Sensory perception in Parkinson's disease. Arch Neurol 1997;54:450-4.
87. Klockgether T, Borutta M, Rapp H., et al. A defect of kinesthe-sia in Parkinson's disease. Brain 1997;120:460-5.
88. Rickards C, Cody FW. Proprioceptive control of wrist move-ments in Parkinson's disease. Brain 1997;120:977-90.
89. Demirci M, Grill S, McShane L, Hallett M. A mismatch between kinesthetic and visual perception in Parkinson's dis-ease. Ann Neurol 1997;41:781-8.
90. Demirci M, Grill S, McShane L, Hallet M. Impairment of kinesthesia in Parkinson's disease. Neurology 1995;45: A218.
91. Albin RL, Young AB, Penny JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366-75.
92. Penny JB, Young AB. Speculations on the functional anatomy of basal ganglia disorders. Annu Rev Neurosci 1983;6:73-94.
93. Berardelli A, Dick JP, Rothwell JC, et al. Scaling of the size of the first agonist EMG burst during rapid wrist movements in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1986;49 1273-9.
94. Ramig LO, Fox CM. LSVT LOUD Training and Certification Workshop Manual. Tucson, AZ: LSVT Global, 2009.
95. Curio G, Neuloh G, Numminen J, et al. Speaking modifies voice-evoked activity in the human auditory cortex. Hum Brain Mapp 2000;9:183-91.
96. Ford JM, Mathalon DH. Electrophysiological evidence of corollary discharge dysfunction in schizophrenia during talk-ing and thinking. J Psychiatr Res 2004;38:37-46.
97. Liotti M, Vogel D, Sapir S, et al. Abnormal auditory gating in Parkinson's disease before and after LSVT. Paper presented at the Annual Meeting of the American Speech, Language and Hearing Association, Washington, DC, 2000.
98. Boecker H, Ceballos-Baumann A, Bartenstein P, et al. Sensory processing in Parkinson's and Huntington's disease: investigations with 3D H215O-PET. Brain 1999;122:1651-65.
99. Cunnington R, Iansek R, Bradshaw JL, Phillips JG. Movement-related potentials in Parkinson's disease. Presence and predictability of temporal and spatial cues. Brain 1995; 118:935-50.
100. Oliveira RM, Gurd JM, Nixon P, et al. Micrographia in Parkinson's disease: the effect of providing external cues. J Neurol Neurosurg Psychiatry 1997;63:429-33.
101. McNamara P, Obler LK, Au R, et al. Speech monitoring skills in Alzheimer's disease, Parkinson's disease, and nor-mal aging. Brain Lang 1992;42:38-51.
102. Rowe J, Stephan KE, Friston K, et al. Attention to action in Parkinson's disease: impaired effective connectivity among frontal cortical regions. Brain 2002;125:276-8.
103. Brown P, Marsden CD. What do the basal ganglia do? Lancet 1999;351:1801-4.
104. Bohnen NI, Kaufer DI, Hendrickson R, et al. (2006) Cogni-tive correlates of cortical cholinergic denervation in Parkin-son's disease and parkinsonian dementia. J Neurol. 253, 242-7.
105. Azulay JP, Mesure S, Blin O. Influence of visual cues on gait in Parkinson's disease: contribution to attention or sensory dependence? J Neurol Sci 2006;248:192-5.
106. Sammer G, Reuter I, Hullmann K, et al. Training of executive functions in Parkinson's disease. J Neurol Sci. 2006;248:115-9.
107. Liotti M, Ramig LO, Vogel D, et al. Hypophonia in Parkin-son's disease. neural correlates of voice treatment revealed by PET. Neurology 2003;60:432-40.
108. Narayana S, Fox PT, Zhang W, et al. Neural correlates of efficacy of voice therapy in Parkinson's disease identified by performance-correlation analysis. Hum Brain Mapp 2010;31, 222-36.
109. Ramig LO, Sapir S, Countryman S, et al. Intensive voice treatment (LSVT) for patients with Parkinson's disease a 2 year follow up. J Neurol Neurosurg Psychiatry 2001;71:493-8.
110. Radad K, Gille G, Rausch W. Short review on dopamine ago-nists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacol. Rep 2005;57:701-12.
111. Critchley EMR. Speech disorders of parkinsonism: a review. J Neurol Neurosurg Psychiatry 1981;44:751-8.
112. Mawdsley C. Speech and levodopa. Adv Neurol 1973;3:33-47.
113. Mawdsley C, Gamsu CV. Periodicity of speech in parkinson-ism. Nature 1971;231:315-6.
114. Nakano KK, Zubick H, Tyley HR Speech defects of parkinsonian patients. Neurology 1973;23:865-70.
115. Rigrodsky S, Morrison EB. Speech changes in parkinsonism during L-dopa therapy: preliminary findings. J Am Geriatr Soc 1970;18:142-51.
116. Wolfe VI, Garvin J, Bacon M, Waldrop W. Speech changes in Parkinson's disease during treatment with l-dopa. J Commun Disord 1975;8:271-9.
117. Yaryura-Tobias JA, Diamond B, Merlis S. Verbal communication with l-dopa treatment. Nature 1971;234:224-5.
118. Hunter PC, Crameri J, Austin S, et al. Response of parkin-sonian swallowing dysfunction to dopaminergic stimulation. J Neurol Neurosurg Psychiatry 1997;63:579-83.
119. Tison F, Wiart L, Guatterie M, et al. Effects of central dopamin-ergic stimulation by apomorphine on swallowing disorders in Parkinson's disease. Mov Disord 1996;11:729-32.
120. Klosterman F, Ehlen F, Vesper J, et al. Effects of subthalamic deep brain stimulation on dysarthrophonia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2008;79:522-9.
121. Tripoliti E, Zrinzo L, Martinez-Torres I, et al. Effects of contact location and voltage amplitude on speech and movement in bilateral subthalamic nucleus deep brain stimulation. Mov Disord 2008;23(16):2377-83.
122. Gallena S, Smith PJ, Zeffiro T, Ludlow CL. Effects of lev-odopa on laryngeal muscle activity for voice onset and offset in Parkinson disease. J Speech Lang Hear Res 2001;44: 1284-99.
123. De Letter M, Santens P, Van Borsel J. The effects of levodopa on word intelligibility in Parkinson's disease. J Commun Dis-ord 2005;38:187-96.
124. Sanabria J, Ruiz PG, Gutierrez R, et al. The effect of levodopa on vocal function in Parkinson's disease. Clin Neuropharmacol 2001;24:99-102.
125. Cahill L, Murdoch BE, Theodoros DG, et al. Effect of oral lev-odopa treatment on articulatory function in Parkinson's disease: preliminary results. Motor Control 1998;2:161-72.
126. Jiang J, Lin E, Wang J, Hanson DG. Glottographic measures before and after levodopa treatment in Parkinson's disease. Laryngoscope 1999;109:1287-94.
127. Biary N, Pimental PA, Langenberg PW. A double-blind trial of clonazepan in the treatment of parkinsonian dysarthria. Neurology 1988;38:255-8.
128. Perlmutter JS, Mink JW. Deep brain stimulation. Annu Rev Neurosci 2006;29:229-57.
129. Pahwa R, Lyons KE, Wilkinson SB, et al. Long-term evalua-tion of deep brain stimulation of the thalamus. J Neurosurg 2006;104:506-12.
130. Rodriguez-Oroz MC, Obeso JA, Lang AE, et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain 2005;128:2240-9.
131. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003;349:1925-34.
132. Santens P, De Letter M, Van Borsel J, et al. Lateral-ized effects of subthalamic nucleus stimulation on different aspects of speech in Parkinson's disease. Brain Lang 2003;87: 253-8.
133. Wang E, Verhagen Metman L, Bakay R, et al. The effect of unilateral electrostimulation of the subthalamic nucleus on respiratory/phonatory subsystems of speech production in Parkinson's disease-a preliminary report. Clin Linguist Phonet 2003;17:283-9.
134. Gentil M, Pinto S, Pollak P, Benabid AL. Effect of bilateral stimulation of the subthalamic nucleus on parkinsonian dysarthria. Brain Lang 2003;85:190-6.
135. Gentil M, Garcia-Ruiz P, Pollak P, Benabid AL Effect of bilateral deep-brain stimulation on oral control of patients with parkinsonism. Eur Neurol 2000;44:147-52.
136. Gentil M, Chauvin P, Pinto S, et al. Effect of bilateral stimulation of the subthalamic nucleus on parkinsonian voice. Brain Lang 2001;78:233-40.
137. Pinto S, Gentil M, Fraix V, et al. Bilateral subthalamic stimulation effects on oral force control in Parkinson's disease. J Neurology 2003;250:179-87.
138. Dromey C, Kumar R, Lang AE, Lozano AM. An investigation of the effects of subthalamic nucleus stimulation on acoustic measures of voice. Mov Disord 2000;15:1132-8.
139. Rousseaux M, Krystkowiak P, Kozlowski O, et al. Effects of subthalamic nucleus stimulation on parkinsonian dysarthria and speech intelligibility. J Neurol 2000;251:327-34.
140. Saint-Cyr JA, Trepanier LL, Kumar R, et al. Neuropsy-chological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease. Brain 2000;123:2091-108.
141. McIntyre CC, Mori S, Sherman DL, et al. Electric field and stimulating influence generated by deep brain stimulation of the subthalamic nucleus. Clin Neurophysiol 2004;115:589-95.
142. Tornqvist AL, Schalen, L, Rehncrona S. Effects of different electrical parameter settings on the intelligibility of speech in patients with Parkinson's disease treated with subthalamic deep brain stimulation. Mov Disord 2005;20:416-23.
143. Dias AE, Barbosa ER, Coracini K, et al. Effects of repetitive transcranial magnetic stimulation on voice and speech in Parkinson's disease. Acta Neurol Scand 2006;113:92-9.
144. Pagni CA, Zeme S, Zenga F. Further experience with extradu-ral motor cortex stimulation for treatment of advanced Parkinson's disease. Report of 3 new cases. J Neurosurg Sci 2003;47:189-93.
145. Berke GS, Gerratt B, Kreiman J, Jackson K. Treatment of parkinson hypophonia with percutaneous collagen augmen-tation. Laryngoscope 1999;109:1295-9.
146. Kim SH, Kearney JJ, Atkins JP. Percutaneous laryngeal colla-gen augmentation for treatment of parkinsonian hypophonia. Otolaryngol Head Neck Surg 2002;126:653-6.
147. Sewall GK, Jiang J, Ford CN. Clinical evaluation of Parkinson's-related dysphonia. Laryngoscope 2006;116:1740-4.
148. Allan CM. Treatment of non-fluent speech resulting from neurological disease: treatment of dysarthria. Br J Disord Com-mun 1970;5:3-5.
149. Greene HCL. The Voice and Its Disorders. London: Pitman Medical, 1980.
150. Weiner WJ, Lang AE. Movement Disorders; a Comprehensive Survey. Mount Kisco, NY: Futura, 1989.
151. Sarno MT. Speech impairment in Parkinson's disease. Arch Phys Med Rehabil 1968;49:269-75.
152. Yorkston KM. Treatment efficacy: dysarthria. J Speech Hear Res 1996;39:S46-57.
153. Adams SG. Hypokinetic dysarthria in Parkinson's disease. In: McNeil MR, ed. Clinical Management of Sensorimotor Speech Disorders. New York: Thieme, 1997.
154. Helm N. Management of palilalia with a pacing board. J Speech Hear Disord 1979;44:350-3.
155. Downie AW, Low JM, Lindsay DD. Speech disorders in parkinsonism: usefulness of delayed auditory feedback in selected cases. Br J Disord Commun 1981;16:135-9.
156. Yorkston KM, Spencer KA, Duffy JR. Behavioral manage-ment of respiratory/phonatory dysfunction from dysarthria: a systematic review of the evidence. J Med Speech Lang Pathol 2003;ll:xiii-xxxviii.
157. Yorkston KM, Hakel, M, Beukelman DR, Fager S. Evidence for effectiveness of treatment of loudness, rate, or prosody in dysarthria: a systematic review. J Med Speech Lang Pathol 2007;15:xi-xxxvi.
158. Pinto S, Ozsancak C, Tripoliti E, Thobois S, et al. Treatments for dysarthria in Parkinson's disease. Lancet Neurol 2004;3:547-56.
159. Ramig L, Mead C, Scherer R, et al. Voice therapy and Parkin-son's disease: a longitudinal study of efficacy. Paper pre-sented at the Clinical Dysarthria Conference, San Diego, CA, February 1988.
160. Smith M, Ramig LO, Dromey C, et al. Intensive voice treat-ment in Parkinson's disease: laryngostroboscopic findings. J Voice 1995;9:453-9.
161. Ramig LO, Dromey C. Aerodynamic mechanisms underlying treatment-related changes in SPL in patients with Parkinson disease. J Speech Hear Res 1996;39:798-807.
162. Countryman S, Hicks J, Ramig L. Supraglottic hyperadduc-tion in an individual with Parkinson disease: treatment outcome. Am J Speech Lang Pathol 1997;6:85-94.
163. Dromey C, Ramig LO, Johnson A. Phonatory and articulatory changes associated with increased vocal intensity in Parkin-son disease: a case study. J Speech Hear Res 1995;38:751-63.
164. Borod JC, Pick LH, Hall S, et al. Relationships among facial, prosodic, and lexical channels of emotional perceptual pro-cessing. Cogn Emotion 2000;14:193-211.
165. Spielman J, Borod J, Ramig L. The effects of intensive voice treatment on facial expressiveness in Parkinson disease: pre-liminary data. Cogn Behav Neurol 2003;16:177-88.
166. Borod JC, Koff E, Lorch MP, Nicholas M. Channels of emo-tional expression in patients with unilateral brain damage. Arch Neurol 1985;42:345-8.
167. Borod JC, Welkowitz J, Alpert M, et al. Parameters of emo-tional processing in neuropsychiatric disorders: conceptual issues and a battery of tests. J Commun Disord 1990;23: 247-71.
168. Canino E, Borod JC, Madigan N, et al. Development of procedures for rating posed emotional expressions across facial, prosodic, and lexical channels. Percept Mot Skills 1999;89:57-71.
169. Ross ED, Mesulam MM. Dominant language functions of the right hemisphere? Prosody and emotional gesturing. Arch Neurol 1979;36:144-8.
170. Porges SW. Orienting in a defensive world: mammalian mod-ifications of our evolutionary heritage. A polyvagal theory. Psychophysiology 1995;32:301-18.
171. Porges SW. Emotion: an evolutionary by-product of the neu-ral regulation of the autonomic nervous system. Ann N Y Acad Sci 1997;807:62-77.
172. Sharkawi AE, Ramig L, Logemann JA, et al. swallowing and voice effects of Lee Silverman Voice Treatment (LSVT): a pilot study. J Neurol Neurosurg Psychiatry 2002;72:31-6.
173. Dromey C, Ramig L. Intentional changes in sound pressure level and rate: their impact on measures of respiration, phonation, and articulation. J Speech Lang Hear Res 1998;41:1003-18.
174. Allen G. Segmental timing control in speech production. J Phonet 1973;1:219-37.
175. Gandour J, Dechongkit S, Ponglorpisit S, Khunadorn F. Speech timing at the sentence level in Thai after unilateral brain damage. Brain Lang 1994;46:419-38.
176. McClean MD, Tasko SM. Association of orofacial with laryn-geal and respiratory motor output during speech. Exp Brain Res 2002;146:481-9.
177. Higgins MB, Netsell R, Schulte L. Vowel-related differences in laryngeal articulatory and phonatory function. J Speech Lang Hear Res 1998;41:712-24.
178. Larson KK, Sapir S. Orolaryngeal reflex responses to changes in affective state. J Speech Lang Hear Res 1995;38:990-1000.
179. Sapir S. The intrinsic pitch of vowels: theoretical, physiologi-cal, and clinical considerations. J Voice 1989;3:44-51.
180. Ackermann H, Wildgruber D, Daum I, Grodd W. Does the cerebellum contribute to cognitive aspects of speech produc-tion? A functional magnetic resonance imaging (fMRI) study in humans. Neurosci Lett 1998;247:187-90.
181. Hirano S, Kojima H, Naito Y, et al. Cortical speech processing mechanisms while vocalizing visually presented languages. NeuroReport 1996;8:363-7.
182. Jurgens U, Kirzinger A, von Cramon D. The effects of deep-reaching lesions in the cortical face area on phonation. A combined case report and experimental monkey study. Cortex 1982;18:125-30.
183. Kitchen DM, Cheney DL, Seyfarth RM. Male chacma baboons (Papio hamadryas ursinus) discriminate loud call contests between rivals of different relative ranks. Anim Cogn 2005;8:1-6.
184. Leinonen L, Laakso ML, Carlson S, Linnankoski I. Shared means and meanings in vocal expression of man and macaque. Logoped. Phoniatr Vocol 2003;28:53-61.
185. Tecumseh W. The phonetic potential of nonhuman vocal tracts: comparative cineradiographic observations of vocaliz-ing animals. Phonetica 2000;57:205-18.
186. Ofer-Noy N, Dudai Y, Karni A. Skill learning in mirror read-ing: how repetition determines acquisition. Cogn Brain Res 2003;17:507-21.
187. Tillerson J, Miller G. Forced limb-use and recovery following brain injury. Neuroscientist 2002;8:574-85.
188. Fisher B, Petzinger G, Nixon K, et al. Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse basal ganglia. J Neurosci Res 2004;77:378-90.
189. Liepert J, Miltner W, Bauder H, et al. Motor cortex plasticity during constraint-induced movement therapy in stroke patients. Neurosci Lett 1998;250:5-8.
190. Kleim J, Jones T, Schallert T. Motor enrichment and the induction of plasticity before or after brain injury, Neurochem Res 2003;11:1757-69.
191. Fox C, Ramig L, Ciucci M, et al. The science and practice of LSVT/LOUD: neural plasticity-principled approach to treat-ing individuals with Parkinson disease and other neurological disorders. Semin Speech Lang 200; 27(4): 283-99.
192. Taub E. Harnessing brain plasticity through behavioral tech-niques to produce new treatments in neurorehabilitation. Am. Psychol 2004;59:692-704.
193. Schmidt RA. A schema theory of discrete motor skill learning. Psychol Rev 1975;82:225-60.
194. Schmidt RA. Motor Control and Learning. Champaign, IL: Human Kinetic Publishers, 1988.
195. Astrand PO, Rodahl K. Textbook of Work Physiology. New York: McGraw-Hill.
196. Stelmach GE. (1991) Basal ganglia impairment and force control. In: Requin J, Stelmach GE, eds. Tutorial in Motor Neuro-science. Dordrecht: Kluwer, 1970.
197. Theodoros DG, Constantinescu G, Russell TG, et al. Treating the speech disorder in Parkinson's disease online. J Telemed Telecare 2006;12:88-91.
198. Howell S, Tripoliti E, Pring T. Delivering the Lee Silverman Voice Treatment (LSVT) by web camera: a feasibility study. J Lang Commun Disord 2009;44:287-300.
199. Halpern AE, Matos C, Ramig L, et al. LSVTC - a PDA sup-ported speech treatment for Parkinson's disease. Presented at the Annual American Speech-Language-Hearing Association Meeting, Philadelphia, PA, 2004.
200. Halpern A, Matos C, Ramig L, et al. LSVTC - a PDA sup-ported speech treatment for Parkinson's disease. Presented at the 9th International Congress of Parkinson's Disease and Movement Disorders, New Orleans, LA, 2005.
201. Rajput A, Rajput AH. Parkinson's disease management strategies. Expert Rev Neurother 2006;6:91-9.
202. Zigmond MJ, Cameron JL, Leak RK, et al. Triggering endogenous neuroprotective processes through exercise in models of dopamine deficiency. Parkinsonism Relat Disord 2009;15(Suppl 3): S42-45.
203. Till JA, Yorkston KM, Beukelman R. Motor Speech Disorders: Advances in Assessment and Treatment. Baltimore, MD: Paul H Brooks, 1994.